<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211510</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 178/Z25/A2</org_study_id>
    <nct_id>NCT00211510</nct_id>
  </id_info>
  <brief_title>Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes</brief_title>
  <acronym>STAR1</acronym>
  <official_title>Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes: A Multi-center, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm
      722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control
      when compared to subjects using the Paradigm 715 insulin pump only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycemic control remains a significant challenge for both adult and adolescent Type 1
      diabetics. Continuous Glucose Monitoring (CGMS) is currently used by clinicians to record
      continuous, retrospective glucose measurements which aid in identification of glycemic
      excursion patterns. This data is then used to make therapy change recommendations for the
      future. The Paradigm 722 System transmits real-time glucose measurements to the insulin pump
      every 5 minutes, allowing users to view their current glucose values, as well as to review
      glycemic excursions and trends over a 24-hour period. This System will alert users to high
      and low glucose levels, and will allow subjects and their clinicians to treat to a
      therapeutic target HbA1c under monitored conditions.

      Subjects wearing the Paradigm 722 System will be compared to subjects wearing the Paradigm
      715 Insulin Pump over a 6 month period to evaluate changes in glycemic control (HbA1c).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1c From Baseline to 26 Weeks</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change is defined as A1c at Week 26 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Severe Hypoglycemia as defined by hypoglycemic events requiring the assistance of another person to actively administer carbohydrates, glucagon or other resuscitative actions, as reported by subject. The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Sensor Accuracy as Measured in the 722 Group</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Percent comparative sensor glucose reading to blood glucose meter in agreement within +/- 20% (Clark Error Grid zone A + zone B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Questionnaire evaluating subjects'potential fear of hypoglycemia events. Change assessed at Baseline and Week 26 and compared between groups. Likert scale scored with 4 being the worst and 0 being no problem.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Paradigm 722 sensor augmented pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 715 insulin pump</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paradigm 722 sensor augmented pump</intervention_name>
    <description>Subjects use the Paradigm 722 sensor augmented pump</description>
    <arm_group_label>Paradigm 722 sensor augmented pump</arm_group_label>
    <other_name>722 pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paradigm 715 insulin pump</intervention_name>
    <description>Subjects use the Paradigm 715 insulin pump</description>
    <arm_group_label>Paradigm 715 insulin pump</arm_group_label>
    <other_name>715 pump</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 12 - 80 years

          -  Type 1 Diabetes Mellitus diagnosed at least 1 year ago

          -  Using insulin infusion pump for past 6 months minimum

          -  Performing minimum 4 blood glucose tests per day

          -  Agree to treat to A1c targets

          -  Read and understand English

        Exclusion Criteria:

          -  Pregnant or planning pregnancy

          -  History of unresolved tape allergy or skin conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Endocrine Group</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Diabetes Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>April 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2011</results_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>Glycemic Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paradigm 722 Sensor Augmented Pump</title>
          <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="P2">
          <title>Paradigm 715 Insulin Pump</title>
          <description>subjects with use the Paradigm 715 insulin pump for insulin infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paradigm 722 Sensor Augmented Pump</title>
          <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="B2">
          <title>Paradigm 715 Insulin Pump</title>
          <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="14.6"/>
                    <measurement group_id="B2" value="32.9" spread="16.3"/>
                    <measurement group_id="B3" value="32.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in A1c From Baseline to 26 Weeks</title>
        <description>Change is defined as A1c at Week 26 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1c From Baseline to 26 Weeks</title>
          <description>Change is defined as A1c at Week 26 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
          <units>Percent glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.69"/>
                    <measurement group_id="O2" value="-0.58" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26</title>
        <description>Severe Hypoglycemia as defined by hypoglycemic events requiring the assistance of another person to actively administer carbohydrates, glucagon or other resuscitative actions, as reported by subject. The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 26.</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26</title>
          <description>Severe Hypoglycemia as defined by hypoglycemic events requiring the assistance of another person to actively administer carbohydrates, glucagon or other resuscitative actions, as reported by subject. The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 26.</description>
          <units>hypoglycemic events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26</title>
        <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26</title>
          <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
          <units>mmol/dl*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.581"/>
                    <measurement group_id="O2" value="0.281" spread="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26</title>
        <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects with use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26</title>
          <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 26</description>
          <units>mmol/dl*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="18.6"/>
                    <measurement group_id="O2" value="-9.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Sensor Accuracy as Measured in the 722 Group</title>
        <description>Percent comparative sensor glucose reading to blood glucose meter in agreement within +/- 20% (Clark Error Grid zone A + zone B).</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Sensor Accuracy as Measured in the 722 Group</title>
          <description>Percent comparative sensor glucose reading to blood glucose meter in agreement within +/- 20% (Clark Error Grid zone A + zone B).</description>
          <units>percent of agreement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9"/>
                    <measurement group_id="O2" value="NA">Subjects in the Paradigm 715 arm did not wear the sensor and so no sensor accuracy could be tested.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups</title>
        <description>Questionnaire evaluating subjects'potential fear of hypoglycemia events. Change assessed at Baseline and Week 26 and compared between groups. Likert scale scored with 4 being the worst and 0 being no problem.</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 722 Sensor Augmented Pump</title>
            <description>subjects will use the Paradigm 711 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 715 Insulin Pump</title>
            <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups</title>
          <description>Questionnaire evaluating subjects'potential fear of hypoglycemia events. Change assessed at Baseline and Week 26 and compared between groups. Likert scale scored with 4 being the worst and 0 being no problem.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.64"/>
                    <measurement group_id="O2" value="-0.22" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Severe adverse event data and adverse device effects were collected for the six month study phase and six month continuation phase that followed.</time_frame>
      <desc>Some hypoglycemia events were self reported and unable to be independently evaluated or verified by the PI, while others had supporting clinical data. Those with supporting data are reported as Systematic, while the self reported events are reported as Non-systematic.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paradigm 722 Sensor Augmented Pump</title>
          <description>subjects will use the Paradigm 722 sensor augmented pump for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="E2">
          <title>Paradigm 715 Insulin Pump</title>
          <description>subjects will use the Paradigm 715 insulin pump for insulin infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Puncture wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <description>Bleeding at sensor insertion site</description>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Shin, PhD, MBA</name_or_title>
      <organization>Medtronic, Inc</organization>
      <phone>818 576 4019</phone>
      <email>john.shin@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

